Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134807 | 1.00 | NR1H4 (0.50) | NR1H4FFAR1ABCC4LMNAGAA | |
| SCHEMBL4120978 | 0.82 | EGFR (0.48) | RORC | |
| SCHEMBL4120979 | 0.82 | EGFR (0.48) | RORC | |
| SCHEMBL4120873 | 0.80 | PTGS1 (0.48) | NR1H4PTGS1PDE4BRORCPDE4D | |
| SCHEMBL4120866 | 0.80 | PTGS1 (0.48) | NR1H4PTGS1PDE4BRORCPDE4D | |
| SCHEMBL4127967 | 0.79 | CTDSP1 (0.42) | NR1H4FFAR1PDE4BPDE4D | |
| SCHEMBL4127965 | 0.79 | CTDSP1 (0.42) | NR1H4FFAR1PDE4BPDE4D | |
| SCHEMBL4132544 | 0.79 | PDE4B (0.42) | GAAPDE4BPDE4D | |
| SCHEMBL4132534 | 0.79 | PDE4B (0.42) | GAAPDE4BPDE4D | |
| SCHEMBL4132445 | 0.77 | FFAR1 (0.47) | NR1H4FFAR1ABCC4LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | NR1H4 2884/4885FFAR1 1878/4885ABCC4 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.